+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are investigating the efficacy and safety of arlo-cel BMS-986393, a GPRC5D-directed CAR-T cell therapy, compared with standard treatment regimens for adults who have relapsed or refractory multiple myeloma and have been previously exposed to lenalidomide. This phase 3, randomized, open-label study aims to assess outcomes in this specific patient group with multiple myeloma. Participants will be assigned to receive either the experimental treatment arlo-cel or one of the standard regimens, which may include drugs such as cyclophosphamide, fludarabine, daratumumab, pomalidomide, dexamethasone, or carfilzomib. Treatments are given at specified doses on scheduled days according to the study protocol. The study is designed with two arms running in parallel to compare these treatment approaches. Throughout the study and for up to five years after the last participant is randomized, researchers will monitor progression-free survival, minimal residual disease status, overall survival, response rates, and quality of life using various established measures. Participants will undergo regular clinical evaluations and assessments to track disease status and treatment effects. Safety and efficacy data will be collected over the long term to better understand the impact of these therapies for multiple myeloma.

Age: 18Years +All GendersPhase 3
141 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TARA-002, a biological preparation containing cells of Streptococcus pyogenes, in adults 18 years and older with high-grade non-muscle invasive bladder cancer NMIBC including carcinoma in situ CIS with or without TaT1. This Phase 2 open-label study aims to further assess TARA-002 at the recommended Phase 2 dose established in a prior dose-finding study. Participants include those who are BCG naive, BCG exposed but not recently treated, or BCG unresponsive. Participants will receive intravesical instillations of TARA-002 in a structured treatment schedule. The first period consists of 6 weekly doses. Those eligible for reinduction will receive another 6 weekly doses, while participants with a complete response after the first period will get 3 weekly maintenance doses. A third treatment period includes 3 weekly maintenance doses administered at months 6, 9, 12, 15, 18, and 24. Following treatment, participants enter a follow-up period lasting from month 27 to month 60. Throughout the study, participants will be monitored for tumor response, including high-grade complete response rates and duration, progression-free survival, cystectomy timing, and survival outcomes up to 60 months. Safety assessments include monitoring adverse events and biomarker changes in urine. Quality of life questionnaires will be administered up to 24 months. This comprehensive evaluation aims to understand TARA-002s effects and safety over time in this patient population.

Age: 18Years +All GendersPhase 2
78 locations